The DOI matches its Crossref record; 138 of the 144 references it cites were found in a registry or an index; 96 of the 238 sources its claims cite were checked for support.
The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism
Open accessAbstract
Endogenous subclinical hyperthyroidism (SHyper) is caused by Graves' disease, autonomously functioning thyroid nodules and multinodular goitre. Its diagnosis is based on a persistently subnormal serum thyroid-stimulating hormone (TSH) level with free thyroid hormone levels within their respective reference intervals. In 2014 the European Thyroid Association Executive Committee, given the controversies regarding the treatment of Endo SHyper, formed a task force to develop clinical practice guidelines based on the principles of evidence-based medicine. The task force recognized that recent meta-analyses, including those based on large prospective cohort studies, indicate that SHyper is associated with increased risk of coronary heart disease mortality, incident atrial fibrillation, heart failure, fractures and excess mortality in patients with serum TSH levels <0.1 mIU/l (grade 2 SHyper). Therefore, despite the absence of randomized prospective trials, there is evidence that treatment is indicated in patients older than 65 years with grade 2 SHyper to potentially avoid these serious cardiovascular events, fractures and the risk of progression to overt hyperthyroidism. Treatment could be considered in patients older than 65 years with TSH levels 0.1-0.39 mIU/l (grade 1 SHyper) because of their increased risk of atrial fibrillation, and might also be reasonable in younger (<65 years) symptomatic patients with grade 2 SHyper because of the risk of progression, especially in the presence of symptoms and/or underlying risk factors or co-morbidity. Finally, the task force concluded that there are no data to support treating SHyper in younger asymptomatic patients with grade 1 SHyper. These patients should be followed without treatment due to the low risk of progression to overt hyperthyroidism and the weaker evidence for adverse health outcomes.
Overview
CoChat Summary
TL;DR
The 2015 European Thyroid Association guidelines define endogenous subclinical hyperthyroidism (SHyper) biochemically as a persistently subnormal serum TSH with normal free thyroxine and triiodothyronine levels, divided into grade 1 (TSH 0.1–0.39 mIU/l) and grade 2 (TSH <0.1 mIU/l). They recommend treating older patients with grade 2 SHyper, considering treatment in older patients with grade 1 SHyper and younger symptomatic patients with grade 2 SHyper, and not treating younger asymptomatic patients with grade 1 SHyper.
Key findings
- SHyper prevalence varies widely, from 0.6 to 16%; in NHANES it was 0.7% with a TSH cutoff <0.1 mIU/l and 1.8% with a cutoff <0.4 mIU/l, and it can be as high as 15% in iodine-deficient subjects >70 years.
- Grade 2 SHyper carries higher risks than grade 1: progression to overt hyperthyroidism was 5–8% per year in grade 2 versus 0.5–0.7% over 7 years in grade 1, and one retrospective study reported progression in 20% of grade 2 versus 6.8% of grade 1 patients over 7 years (p < 0.001).
- Meta-analyses showed increased risks with SHyper, especially grade 2: incident atrial fibrillation HR 2.54 (95% CI 1.08–5.99) for grade 2 and 1.63 (95% CI 1.10–2.41) for grade 1; heart failure HR 1.94 (95% CI 1.01–3.72) for grade 2 and 1.31 (95% CI 0.88–1.95) for grade 1; total mortality HR 1.24 (95% CI 1.06–1.46); CHD mortality HR 1.84 (95% CI 1.12–3.00) for grade 2; fracture HRs were 1.52 (95% CI 1.19–1.93) for hip fracture, 1.42 (95% CI 1.16–1.74) for any fracture, and 1.74 (95% CI 1.01–2.99) for spine fracture.
- Treatment recommendations: treat patients >65 years with grade 2 SHyper (1/++0); consider treatment in patients >65 years with grade 1 SHyper (2/+00); suggest treating patients <65 years with persistent and/or symptomatic grade 2 SHyper (2/+00); and do not recommend treating young asymptomatic patients with grade 1 SHyper (2/+00). ATDs are first choice in young patients with Graves’ disease and grade 2 SHyper and in patients >65 years with Graves’ disease and grade 1 SHyper; RAI or surgery is preferred for older patients with toxic multinodular goitre or toxic adenoma.
Methods
- An ETA task force was formed in 2014 and performed a systematic literature review searching Medline for “subclinical hyperthyroidism” from May 1974 to July 2015, restricted to English-language reports but including translated articles, plus personal files and references.
- The task force used the GRADE system, rating recommendation strength as 1 (strong) or 2 (weak) and evidence quality as +++ (high, level A), ++0 (moderate, level B), or +00 (low, level C); because few randomized controlled trials were available, nonrandomized trials and expert opinions were also considered.
- Draft recommendations were posted on the ETA members-only website for 4 weeks, comments were incorporated, and the final document was approved by the ETA Guidelines Board and Executive Committee.
Limitations
- The paper states that there are no randomized prospective trials demonstrating that treatment of SHyper improves the associated cardiovascular and skeletal risks, and that two European trials were terminated because they did not complete recruitment.
- The paper states that in most prospective studies thyroid function was measured only at baseline, FT3 was measured in only a few cohorts, and the aetiology of hyperthyroidism was not considered.
- Evident from the text: many recommendations rely on observational cohort studies, meta-analyses of individual participant data, and expert opinion, with several recommendations graded weak (2) and/or supported by low-quality evidence (+00); treatment benefit itself remains unproven in randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
70 Valid · 4 Not valid · 86 Not checked · 11 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A recent retrospective Danish cohort study, which was not included in the meta-analysis by Gencer et al. [75] , reported a trend for increased risk for major adverse cardiac events and HF with increasing degree of hyperthyroidism [77] .”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Risk of Heart Failure
What the sources say
- Disputedcites [77] Selmer C, Olesen JB, Hansen ML, et al: Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab 2014;99:2372-2382.10.1210/jc.2013-418424654753 sourceExperimental — accuracy not yet measured
The Hyperthyroid states results report a trend with increasing hyperthyroidism for all-cause mortality, not for MACE or heart failure. They describe MACE risk as elevated in both subclinical and overt hyperthyroidism, while the discussion says the study could not demonstrate a clear dose-dependent relationship with decreasing TSH. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Radioiodine may induce hypothyroidism and ATDs may increase and reduce the rate of hypothyroidism when given in the week before or after radioiodine treatment, respectively [122] .”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Potential Adverse Effects during Treatment with ATDs, RAI and Surgery
What the sources say
- Disputedcites [122] Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, Bucher HC, Müller-Brand J, Müller B: Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 2007;10;334:514.10.1136/bmj.39114.670150.BE17309884 sourceExperimental — accuracy not yet measured
The Hypothyroidism section reports a risk ratio of 0.76 for hypothyroidism when antithyroid drugs were given before radioiodine treatment, indicating a possible reduction, not an increase; the confidence interval includes no effect. The Discussion also describes reduced hypothyroidism rates with antithyroid drugs given in the week before or after treatment. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cardiovascular symptoms are the most frequent indicators of mild thyroid hormone excess in the elderly, similar to overt hyperthyroidism [52,53] .”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Symptoms of Hyperthyroidism, Quality of Life, Cognitive Impairment or Dementia in Patients with SHyper
What the sources say
- Partly supportedcites [52] Sawin CT, Geller A, Wolf PA, et al: Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249-1252.10.1056/NEJM1994111033119017935681 sourceExperimental — accuracy not yet measured
The Discussion (p. 3) identifies atrial fibrillation as a manifestation associated with overt hyperthyroidism and finds that low thyrotropin is a risk factor for it in people aged 60 or older. The paper does not establish that cardiovascular symptoms are the most frequent indicators of mild thyroid hormone excess; it defines subclinical hyperthyroidism in an asymptomatic person (p. 1). (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [53] Cappola AR, Fried LP, Arnold AM, et al: Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006;295:1033-1041.10.1001/jama.295.9.103316507804 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“At variance, two recent prospective studies did not find an association between low serum TSH levels and the risk of cognitive impairment and dementia or decreased functional capacity in the elderly [61,62] .”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Symptoms of Hyperthyroidism, Quality of Life, Cognitive Impairment or Dementia in Patients with SHyper
What the sources say
- Partly supportedcites [61] Wijsman LW, de Craen AJ, Trompet S, Gussekloo J, Stott DJ, Rodondi N, Welsh P, Jukema JW, Westendorp RG, Mooijaart SP: Subclinical thyroid dysfunction and cognitive decline in old age. PLoS One 2013;8:e59199.10.1371/journal.pone.005919923554996 sourceExperimental — accuracy not yet measured
The Discussion reports no association between subclinical thyroid dysfunction and cognitive performance or decline in participants aged 70–82 with vascular disease or risk factors. The Methods define low TSH as subclinical hyperthyroidism, so this supports the cognitive portion of the claim. The study did not report prospective risks of dementia or decreased functional capacity; its functional-capacity scores appear only as baseline characteristics in the Results. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [62] Virgini VS, Wijsman LW, Rodondi N, Bauer DC, Kearney PM, Gussekloo J, den Elzen WP, Jukema JW, Westendorp RG, Ford I, Stott DJ, Mooijaart SP; PROSPER Study Group: Subclinical thyroid dysfunction and functional capacity among elderly. Thyroid 2014;24:208-214.10.1089/thy.2013.007123941540 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, hyperthyroidism itself has been associated with a prothrombotic state [78,79] .”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Risk of Stroke
What the sources say
- Partly supportedcites [78] Squizzato A, Gerdes VE, Brandjes DP, Büller HR, Stam J: Thyroid diseases and cerebrovascular disease. Stroke 2005;36:2302-2310.10.1161/01.STR.0000181772.78492.0716179578 sourceExperimental — accuracy not yet measured
The Conclusion says in vivo and in vitro studies suggest increased thrombotic risk in thyrotoxicosis, supporting a possible prothrombotic association. It also says evidence is insufficient to establish increased cardioembolic risk from hypercoagulability, so the claim should not be read as an established clinical association. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [79] Schultz M, Kistorp C, Raymond I, Dimsits J, Tuxen C, Hildebrandt P, Faber J: Cardiovascular events in thyroid disease: a population based, prospective study. Horm Metab Res 2011;43:653-659.10.1055/s-0031-128316221823062 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
123 more claims · 55 with their cited sources checked
Create a free account to see all 171 claims and every source verdict.
- It may state two separate claims as one. 37
- Probably not a substantial claim. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has widely been assumed that these associations are caused by subclinical hyperthyroidism with detrimental effects of excess thyroid hormone, for instance its proarrhythmic effect on the heart leading to AF, despite the fact that serum thyroid hormones are within reference range (1, 13–15, 29, 41, 42).”
From Serum Thyroid Function, Mortality and Disability in Advanced Old Age: The Newcastle 85+ Study (2016) · cites this paper as [41]
In the citing paper
“The European Thyroid Association recently reviewed these data and published guidelines for the treatment of subclinical hyperthyroidism, which are largely concordant with recommendations presented here (428).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [428]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Five meta-analyses assessed the risk of cardiovascular and allcause mortality in patients with SHyper [71,[89][90][91][92][93] .Two did not find a link between SHyper and mortality [89,90] , whereas four other meta-analyses found an association between SHyper and cardiovascular or all-cause mortality”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Cardiovascular Mortality and Coronary Heart Disease Events and Mortality
Reported 5 · recomputed 6
Citations
Cites
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
Hollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., & Braverman, L. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.489 · Cited by 4,279
The Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000040 · Cited by 2,056
Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management
Surks, M. I., Ortiz, E., Daniels, G. H., Sawin, C. T., Col, N. F., Cobin, R. H., Franklyn, J. A., Hershman, J. M., Burman, K. D., Denke, M. A., et al. (2004) · JAMA · doi:10.1001/jama.291.2.228 · Cited by 1,800
The Clinical Significance of Subclinical Thyroid Dysfunction
Biondi, B., & Cooper, D. S. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0043 · Cited by 1,418
Self-citationLow Serum Thyrotropin Concentrations as a Risk Factor for Atrial Fibrillation in Older Persons
Sawin, C. T., Geller, A., Wolf, P. A., Belanger, A. J., Baker, E., Bacharach, P., Wilson, P., Benjamin, E. J., & D'Agostino, R. B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311901 · Cited by 1,259
Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease
(2003) · Thyroid · doi:10.1089/105072503321086962 · Cited by 1,212
Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., Rivkees, S. A., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.3.456 · Cited by 1,098
Cooper, D. S., & Biondi, B. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60276-6 · Cited by 1,039
Self-citation
Cited by
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938
Self-citation2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism
Kahaly, G. J., Bartalena, L., Hegedüs, L., Leenhardt, L., Poppe, K., & Pearce, S. H. (2018) · European Thyroid Journal · doi:10.1159/000490384 · Cited by 940
Self-citationThyroid hormones and cardiovascular disease
Jabbar, A., Pingitore, A., Pearce, S. H. S., Zaman, A., Iervasi, G., & Razvi, S. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.174 · Cited by 729
Thyroid dysfunction and diabetes mellitus: two closely associated disorders
Biondi, B., Kahaly, G. J., & Robertson, R. P. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00163 · Cited by 598
Self-citationThyroid Hormones and Cardiovascular Function and Diseases
Razvi, S., Jabbar, A., Pingitore, A., Danzi, S., Biondi, B., Klein, I., Peeters, R., Zaman, A., & Iervasi, G. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.045 · Cited by 515
“1 mIU/l) in patients older than 65 years of age and in younger patients with comorbidities (81,82).”
BackgroundSelf-citation
Metadata
- Authors
- Biondi, B., Bartalena, L., Cooper, D. S., Hegedüs, L., Laurberg, P., & Kahaly, G. J.
- Affiliations
- Federico II University Hospital (IT)
- University of Insubria (IT)
- Johns Hopkins University (US)
- 4Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark
- Aalborg University Hospital (DK)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Venue
- European Thyroid Journal
- Publisher
- Bioscientifica
- Published
- 2015-08-26
- Volume
- 4
- Issue
- 3
- Pages
- 149-163
- ISSN
- 2235-0640 (ISSN-L)
- 2235-0802
- PMC
- PMC4637513
- OpenAlex
- W1562308323
- Semantic Scholar
- 818f295aa3f0f01a788efe5b483e264f688279b3
- Cited by
- 323
- References
- 144
- Citations by year
- 2026: 18 · 2025: 26 · 2024: 34 · 2023: 27 · 2022: 32 · 2021: 39 · 2020: 40 · 2019: 16 · 2018: 38 · 2017: 30 · 2016: 20 · 2015: 3
- FWCI
- 26.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Thyroid Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (publishedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, other-oa)
- IrInSubria (University of Insubria) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- subclinical hyperthyroidism, Graves' disease, autonomously functioning thyroid nodules, multinodular goiter, thyroid-stimulating hormone, cardiovascular risk, atrial fibrillation, heart failure, fracture, elderly patients, treatment indications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. https://app.cochat.ai/papers/10.1159/000438750
- The paper
- Biondi, B., Bartalena, L., Cooper, D. S., Hegedüs, L., Laurberg, P., & Kahaly, G. J. (2015). The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. European Thyroid Journal. https://doi.org/10.1159/000438750
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.